Prime Therapeutics picks both PCSK9s

Pharmacy benefits manager Prime Therapeutics said it will offer co-preferred status on its national formulary for Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN) and Praluent alirocumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY).

In August, Prime said it expected to choose one drug; on Tuesday the PBM said it considers the treatments "clinically equivalent." Chief Clinical Officer David Lassen told BioCentury that Prime's choice was "the best financial decision for our plans" (see BioCentury Extra, Aug. 28). ...